FDA Brief

Warning letters Drugs

FDA warning letter to

Bi-Coastal Pharma International

High riskIssued Jun 30, 2022Posted Jul 26, 2022Office of Pharmaceutical Quality Operations Division I

FDA warned Bi-Coastal Pharma International about adulterated drugs due to poor complaint handling, quality-unit oversight, batch release, and training.

What happened

FDA inspected Bi-Coastal Pharma International's drug manufacturing facility in Shrewsbury, New Jersey, from December 15, 2021, to January 14, 2022. FDA found that the company did not investigate an adverse reaction complaint for Chlordiazepoxide HCl and Clidinium Br, lacked adequate quality-unit oversight of contract manufacturers, released batches without receiving or verifying executed batch records, and had an unqualified QA manager.

What FDA found

  1. Failed to investigate a June 2, 2020, adverse reaction complaint for Chlordiazepoxide HCl and Clidinium Br, including whether the product failed specifications or needed an investigation.

    21 CFR 211.198(a)
  2. Failed to establish adequate written quality-unit responsibilities and procedures for overseeing contract manufacturers, including review of out-of-specification results, deviations, complaints, and change controls.

    21 CFR 211.22(a) and (d)
  3. Failed to follow its batch record review and release procedure; it did not receive or verify executed batch records for numerous distributed batches since December 2019 and released a Hydroquinone Gel 4% lot without a required 'Reviewed by' signature.

    21 CFR 211.22(a) and (d)
  4. Failed to ensure the QA manager had the education, training, or experience for quality oversight and was unaware of CGMP stability testing and process validation requirements.

    21 CFR 211.25(b)

What FDA wants

Respond in writing within 15 working days with corrective actions and assessments or plans for complaint investigations, the quality unit and CMO oversight, batch release, and training; if corrective actions cannot be completed in that time, state the reasons and a completion schedule. FDA also strongly recommends a qualified CGMP consultant.

Who should pay attention

  • drug companies that rely on contract manufacturers
  • product owners and distributors with outsourced quality oversight
  • quality teams handling complaints and batch release

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk